Scorpion Capital Shorts Twist Bioscience, Calls AI Drug Story a 'Speculative Delusion'
TWST has more than doubled off its 52-week low of $23.3 on elevated volume (2.0× avg).
Summary
Scorpion Capital published a short report on X, calling Twist's AI drug-discovery narrative a 'speculative delusion' and arguing the Anthropic deal is merely a commodity CRO arrangement. The short seller claims Anthropic's higher protein-binding success rates are deflationary for Twist's revenue. Despite the report, TWST closed up 22.64% at $142.39, a new 52-week high, showing no negative reaction. This follows the earlier Dow Jones report that Anthropic selected Twist as an independent evaluator. The stock's resilience suggests the market is dismissing the short thesis for now, but the short position is now public and could pressure shares if the narrative shifts.
At the time of this announcement, TWST was trading at $140.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4B. The 52-week trading range was $23.30 to $142.84. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.